{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DMMR+Solid+Malignant+Tumor&page=2",
    "query": {
      "condition": "DMMR Solid Malignant Tumor",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DMMR+Solid+Malignant+Tumor&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T13:32:09.887Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Astrocytoma, IDH-Mutant",
        "Glioblastoma, IDH-wildtype",
        "Brain Metastases, Adult",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Microsatellite Instability-High Solid Malignant Tumor",
        "Mismatch Repair Deficient Solid Malignant Tumor",
        "Microsatellite Instability-High Colorectal Cancer",
        "Mismatch Repair Deficient Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Small Cell Lung Cancer",
        "Squamous Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "NEO212 Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI Protocol",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neonc Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2023-11-01",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 6,
      "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 3 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06047379"
    },
    {
      "nct_id": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Unresectable Solid Tumor",
        "Clear Cell Renal Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Non-Small Cell Lung Cancer Squamous",
        "Non-Small Cell Lung Cancer Non-squamous",
        "Colorectal Cancer (MSI-H)",
        "Gastric Cancer",
        "Cervical Cancer",
        "Basal Cell Carcinoma",
        "Bladder Cancer",
        "Merkel Cell Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Cutaneous Squamous Cell Carcinoma",
        "Pleural Mesothelioma",
        "Esophageal Cancer",
        "Endometrial Carcinoma",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "MSI-H Solid Malignant Tumor",
        "Cancer With A High Tumor Mutational Burden",
        "Epithelial Ovarian Carcinoma",
        "Primary Peritoneal Cancer",
        "Gastroesophageal Junction (GEJ) Cancer",
        "Acral Melanoma",
        "Mucosal Melanoma",
        "Cutaneous Melanoma",
        "DMMR Solid Malignant Tumor",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "MSI-H Cancer",
        "DMMR Cancer",
        "Pancreas Adenocarcinoma (MSI-H)",
        "Skin Cancer",
        "Viral Cancer",
        "Cervical Cancers",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "MDNA11",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicenna Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2021-08-27",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 7,
      "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05086692"
    },
    {
      "nct_id": "NCT03589339",
      "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiotherapy",
        "Immunotherapy",
        "Microsatellite Instability-High Solid Malignant Tumour",
        "Metastasis From Malignant Tumor of Liver",
        "Squamous Cell Carcinoma of Head and Neck",
        "Metastasis From Malignant Tumor of Cervix",
        "Metastatic Renal Cell Carcinoma",
        "Metastasis From Malignant Melanoma of Skin (Disorder)",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic NSCLC",
        "Metastasis From Malignant Tumor of Bladder (Disorder)"
      ],
      "interventions": [
        {
          "name": "NBTXR3",
          "type": "DRUG"
        },
        {
          "name": "SABR",
          "type": "RADIATION"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Nanobiotix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2019-01-16",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03589339"
    },
    {
      "nct_id": "NCT04242199",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "MSI-H/dMMR Tumors",
        "Cutaneous Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "Cervical Cancer",
        "HepatoCellular Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Mesothelioma",
        "PD-L1 Amplified Tumor (9p24.1)",
        "Nasopharyngeal Carcinoma"
      ],
      "interventions": [
        {
          "name": "INCB099280",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2020-09-04",
      "completion_date": "2024-11-21",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04242199"
    },
    {
      "nct_id": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "VIP152 (BAY 1251152)",
          "type": "DRUG"
        },
        {
          "name": "VIP152 (BAY 1251152) 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Keytruda",
          "type": "DRUG"
        },
        {
          "name": "VIP152 (BAY 1251152) 15 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vincerx Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2016-02-10",
      "completion_date": "2024-11-11",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 13,
      "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02635672"
    },
    {
      "nct_id": "NCT04041310",
      "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "GAd-209-FSP low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GAd-209-FSP high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GAd20-209-FSP, RP2D",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP, RP2D",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KEYTRUDA®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nouscom SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2019-10-21",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04041310"
    },
    {
      "nct_id": "NCT04082572",
      "title": "Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2019-10-31",
      "completion_date": "2024-11-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-13",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04082572"
    },
    {
      "nct_id": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Melanoma",
        "Metastasis",
        "Pleural Mesothelioma",
        "Renal Cell Carcinoma",
        "MSI-High",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer",
        "Hepatocellular Carcinoma",
        "Hepatocellular Cancer",
        "Renal Cell Cancer",
        "Kidney Cancer",
        "Skin Cancer",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",
        "ALK Genomic Tumor Aberrations"
      ],
      "interventions": [
        {
          "name": "Alintegimod",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "7 Hills Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2024-08-23",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06362369"
    },
    {
      "nct_id": "NCT06004245",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "VVD-133214",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vividion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2024-01-25",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Irvine, California • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06004245"
    },
    {
      "nct_id": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ad-p53",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MultiVir, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-10-01",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-06-25T13:32:09.887Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Morristown, New Jersey",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03544723"
    }
  ]
}